AS DECEMBER DRAWS to a close, there have been a number of “happenings” in health care, both nationally and locally, that have major implications for policy. A few are worth pondering as we approach a new year, particularly since they are puzzling to me. Failure of a federal surprise bill and out-of-network payment legislation How […]
Paul Hattis
Five takeaways from the Health Policy Commission hearing
THERE HAVE BEEN SEVEN Health Policy Commission cost trend hearings since 2013, but the one that took place recently was the most interesting. Part of it was timing – Gov. Charlie Baker is pushing major health care legislation and national health care policy is in flux – but part of it was also the players […]
Money for nothing
MASSACHUSETTS HOSPITALS appear to be getting more money while providing no added value to patients. Patients, premium payers, and the state or federal governments (funded by our payroll or income taxes) are footing the bill. As reported recently in Commonwealth, the Health Policy Commission research team at the agency’s September 11 board meeting presented data […]
What consumers deserve from Harvard Pilgrim-Tufts merger
WHEN I SPEAK with colleagues around the country about how expensive health care is in Eastern Massachusetts, I tend to place most of the blame on our large and prestigious health care provider systems that demand very high prices. More recently, I have also noted that pharma prices, fueled by patent protection for newer drugs and […]
Medicare for All interim steps
WHETHER YOU ARE an avid supporter of the Bernie Sanders-style single-source financing concept (often referred to these days as Medicare For All), dead set against it, or somewhere in-between, you have to admit, there is significant market dysfunction in the provision of goods and services in our nation’s health care system, including here in Massachusetts. […]
MassBIO’s drug pricing concerns don’t add up
ONE OF THE MORE PUZZLING arguments the Massachusetts biopharma industry is putting forward during the Beacon Hill debate over Medicaid drug pricing is that innovative drugs won’t be developed and the state economy will suffer if the approach favored by Gov. Charlie Baker and the Senate becomes law. The argument is simply poppycock. The reality […]
Time for Tufts soul-searching on Purdue Pharma
AS A FACULTY MEMBER at Tufts University School of Medicine, I, along with colleagues and many of our students, have found it embarrassing to be confronted by news reports on how our medical school and university have been taking money over a number of years from Purdue Pharmaceuticals, the family that owns the company, and […]
A pitch for socializing corporate health insurance premiums
LAST WEEKEND I attended the memorial service for Rob Restuccia, a longtime and pioneering advocate for a more just and consumer responsive health care system in Massachusetts, and really across the US. For many, and for me since I moved to Massachusetts in 1992, Rob served as a teacher, mentor, inspirational leader, and advisor on […]
Partners is like a shark – always on the move
Second of two parts AS A BIG, COMPLEX SYSTEM that pursues diverse missions of clinical care, research, teaching, and community benefit, Partners HealthCare has an almost insatiable need to significantly grow its revenue base each year. The need is only fueled by their almost never-ending desire to take on one major capital project after another; […]
Are the Partners hospitals really partners?
First of two parts PARTNERS HEALTHCARE has been in the news a lot lately. First, on January 22, Partners started to spread the word about a plan for Massachusetts General Hospital to build a 12-story, two-tower facility on its main campus for inpatient and outpatient care. The new inpatient facility will include 450 beds in […]